HIV–HBV-coinfected individuals who need to be treated only for their HBV infection have limited therapeutic options, since most approved anti-HBV agents have a risk of selecting for drug-resistant HIV mutants. In vivo data are inconclusive as to whether telbivudine (LdT) may exert antiviral effects against HIV. Thus, we investigated in further detail the antiviral activity and the biochemical properties of LdT against HIV-1.
Methods
To investigate the activity of LdT against HIV-1 in humans we analysed viral dynamics and genotypic and phenotypic resistance development in two HIV–HBV-coinfected individuals with no prior antiviral exposure. To investigate the activity of LdT against HIV-1 in vitro, LdT susceptibility for HIV-1 wild-type strains as well as drug-resistant strains was determined. Furthermore, we studied whether the 5′-triphosphate form of LdT (LdT-TP) can act as a substrate for wild-type HIV-1 RT.
Results
In the two patients studied, LdT treatment did not result in a significant decline of HIV-1 RNA load nor in selection of genotypic or phenotypic resistance in HIV-1 RT. In vitro virological analyses demonstrated that LdT had no activity (50% effective concentration >100 μM) against wild type HIV and drug-resistant variants. Biochemical analyses demonstrated that LdT-TP is not incorporated by wild-type HIV-1 RT.
Conclusions
Based on the in vivo and in vitro evidence obtained in this study, we conclude that LdT has no anti-HIV-1 activity and is currently the only selective anti-HBV agent among the five FDA-approved nucleoside/nucleotide analogues for treatment of HBV infections in HIV-infected individuals.
References
1.
SorianoV., TumaP., VispoE.Hepatitis B in HIV patients: what is the current treatment and what are the challenges?J HIV Ther2009; 14: 13–18.
2.
JainM.K., ZoellnerC.L.Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naive patient treated for chronic HBV. AIDS2007; 21: 2365–2366.
3.
JakobsenM.R., ArildsenH., KrarupH.B.Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient. Clin Infect Dis2008; 46: e88–e91.
4.
McMahonM.A., JilekB.L., BrennanT.P.The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med2007; 356: 2614–2621.
5.
SasadeuszJ., AudsleyJ., MijchA.The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS2008; 22: 947–955.
6.
LinP.F., Nowicka-SansB., TerryB.Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob Agents Chemother2008; 52: 1759–1767.
7.
DomaoalR.A., McMahonM., ThioC.L.Pre-steadystate kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem2008; 283: 5452–5459.
8.
TchesnokovE.P., ObikhodA., SchinaziR.F.Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem2008; 283: 34218–34228.
9.
BryantM.L., BridgesE.G., PlacidiL.Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother2001; 45: 229–235.
10.
LinK., KarwowskaS., LamE.Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. Antimicrob Agents Chemother2010; 54: 2670–2673.
11.
StandringD.N., BridgesE.G., PlacidiL.Antiviral beta-l-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother2001; 12Suppl 1: 119–129.
12.
LowE., CoxA., AtkinsM.Telbivudine has activity against HIV-1. AIDS2009; 23: 546–547.
13.
MilazzoL., CarammaI., LaiA.Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. Antivir Ther2009; 14: 869–872.
14.
PasS.D., NiestersH.G.Detection of HBV DNA using real time analysis. J Clin Virol2002; 25: 93–94.
15.
van MaarseveenN.M., HuigenM.C., de JongD., SmitsA.M., BoucherC.A., NijhuisM.A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. J Virol Methods2006; 133: 185–194.
16.
BoucherC.A., KeulenW., van BommelT.Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother1996; 40: 2404–2409.
17.
HuigenM.C., de GraafL., EgginkD.Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase. Virology2007; 364: 395–406.
18.
Le GriceS.F., CameronC.E., BenkovicS.J.Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol1995; 262: 130–144.
19.
LevineS., HernandezD., YamanakaG.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother2002; 46: 2525–2532.
20.
JohnsonV.A., Brun-VezinetF., ClotetB.Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med2009; 17: 138–145.
21.
LiawY.F., GaneE., LeungN.2-Year GLOBE Trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology2009; 136: 486–495.
